Bausch Health Companies Logo
CA0717341071
A2JQ1X
BHC

Bausch Health Companies

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 8,48 € (+50,89%). La mediana è 7,33 € (+30,43%).

Acquista
  19
Mantieni
  15
Vendi
  4

  • Bausch Health launches Fraxel FTX laser system in Australia via Solta Medical

    Bausch Health, through its aesthetics division Solta Medical, is introducing the Fraxel FTX laser system in Australia. The upgraded system uses two wavelengths (1927 nm for the epidermis, 1550 nm for the dermis), creates microscopic treatment zones and targets indications such as fine lines, wrinkles, acne scars, pigment lesions, as well as actinic keratosis and melasma. Innovations include a lighter handpiece, integrated cooling, AccuTRAC tracking and a modernized user interface; the device is prescription-only and will be supported by Solta Medical with clinical and hands-on training. » Altro su de.investing.com


  • Bausch Health falls to 52-week low of $4.56

    Bausch Health shares closed at $4.56, marking a 52-week low and a one-year performance of -28.42%. Analysts nevertheless see upside and cite price targets between $6 and $9, while data from InvestingPro classify the stock as undervalued. Investors are watching the quarterly report due in eight days, seen as a potential turning point for the $1.75 billion pharmaceutical group. » Altro su de.investing.com


  • Bausch Health's PrOKEDI 75mg and 100mg listed in Quebec RAMQ formulary

    Bausch Health Canada secured listing of PrOKEDI 75mg and 100mg dosages in the Régie de l'assurance maladie du Québec formulary, marking a key reimbursement milestone for the injectable risperidone treatment for adults with schizophrenia. PrOKEDI provides rapid therapeutic concentrations without oral supplementation or a loading dose and offers four-week dosing. The company said it will pursue coverage in other provinces following a prior Letter of Intent from the pan-Canadian Pharmaceutical Alliance to advance public drug program access. » Altro su finance.yahoo.com

Nel 2010, Bausch Health Companies ha già distribuito 1,04 € di dividendi. L'ultimo pagamento è avvenuto a dicembre 2010.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Bausch Health Companies ha registrato ricavi pari a 2,5 Mld € e un utile netto di 226,06 Mln €
(EUR) giu 2026
YoY
Ricavi 2,5 Mld 16,42%
Utile lordo 1,82 Mld 21,64%
Utile netto 226,06 Mln 80,03%
EBITDA 898,12 Mln 16,07%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
2,15 Mld €
Numero di azioni
373,99 Mln
Massimo/minimo a 52 settimane
6,90 € - 3,73 €
Dividendi No
Beta
0,38
Rapporto P/E
-2,26
Rapporto PEG
0,00
Rapporto P/B
-1,41
Rapporto P/S
0,23

Profilo aziendale

Bausch Health Companies Inc. entwickelt, produziert und vermarktet zusammen mit seinen Tochtergesellschaften eine Reihe von pharmazeutischen Produkten, Medizinprodukten und rezeptfreien Produkten, vor allem in den therapeutischen Bereichen Augenheilkunde, Gastroenterologie und Dermatologie. Das Unternehmen ist in fünf Segmenten tätig: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics und Diversified Products. Das Segment Bausch + Lomb bietet Produkte mit den Schwerpunkten Sehhilfen, chirurgische und Verbraucherprodukte, chirurgische und ophthalmologische Arzneimittel an. Das Segment Salix bietet Produkte für die Gastroenterologie in den Vereinigten Staaten an. Das Segment International Rx bietet Solta-Produkte, pharmazeutische Markenprodukte und Generika, OTC-Produkte und medizintechnische Produkte sowie Produkte von Bausch + Lomb in Kanada, Europa, Asien, Australien, Lateinamerika, Afrika und dem Nahen Osten an. Das Segment Ortho Dermatologics bietet dermatologische Produkte in den Vereinigten Staaten und Solta medizinisch-ästhetische Geräte international an. Das Segment Diversified Products bietet pharmazeutische Produkte in den Bereichen Neurologie und andere therapeutische Klassen sowie Generika und zahnmedizinische Produkte in den Vereinigten Staaten an. Das Unternehmen war früher als Valeant Pharmaceuticals International, Inc. bekannt und änderte im Juli 2018 seinen Namen in Bausch Health Companies Inc. Der Hauptsitz von Bausch Health Companies Inc. befindet sich in Laval, Kanada.

Nome
Bausch Health Companies
CEO
Thomas J. Appio
Sede centrale Laval, qc
Canada
Sito web
Settore
Sanità
Industria
Prodotti farmaceutici
Quotazione in borsa
29/03/1994
Dipendenti 20.300

Simboli di borsa

Borsa Simbolo
NYSE
BHC
Toronto Stock Exchange
BHC.TO
Frankfurt
BVF.F
Düsseldorf
BVF.DU
SIX
VRX.SW
München
BVF.MU

Scopri gli asset

Gli azionisti di Bausch Health Companies investono anche nei seguenti asset

🍪

Parqet  usa i cookie. Scopri di più